Payment models

The need for performance-based payment models is likely to increase in the future, not least due to stepwise introduction of new therapies and rapid developments within the field of ATMP.

IHE has a long-standing interest in the development of new payment models in order to

  • reduce uncertainty around costs and benefits
  • optimize and individualize treatments to avoid over- or under treatment
  • drive faster uptake of new, effective pharmaceuticals
  • stimulate the development of new technologies

Examples of areas where IHE has developed new payment models include haemophilia, multiple sclerosis and psoriasis.